{"id":70723,"date":"2026-05-12T09:57:27","date_gmt":"2026-05-12T09:57:27","guid":{"rendered":"https:\/\/medsbase.com\/?post_type=product&#038;p=70723"},"modified":"2026-10-15T10:33:58","modified_gmt":"2026-10-15T10:33:58","slug":"kisspeptin-10","status":"publish","type":"product","link":"https:\/\/medsbase.com\/es\/product\/kisspeptin-10\/","title":{"rendered":"Kisspeptina-10"},"content":{"rendered":"<p><!-- medsbase-tldr-answer --><\/p>\n<div style=\"background: #fff8e1; border-left: 4px solid #f5a623; padding: 18px 22px; margin: 18px 0; border-radius: 4px;\">\n<h3 style=\"margin: 0 0 8px 0; font-size: 16px; color: #1a4a6b;\">Respuesta r\u00e1pida \u2014 \u00bfQu\u00e9 es la Kisspeptina-10?<\/h3>\n<p style=\"margin: 0;\"><strong>Kisspeptina-10<\/strong> (KP-10) is a 10-amino-acid C-terminally amidated peptide and the most-studied active fragment of the KISS1 gene product. It is the apical endogenous regulator of GnRH neuronal activity \u2014 published studies established it as the upstream switch that initiates puberty and drives pulsatile gonadotropin release. Acts via the GPR54 (KISS1R) G-protein-coupled receptor. Supplied in 5\u00a0mg and 10\u00a0mg lyophilized vials.<\/p>\n<\/div>\n<div class=\"medsbase-trust-strip\" style=\"background: #f4f8fb; border: 1px solid #d8e3eb; padding: 12px 16px; margin: 16px 0; border-radius: 4px; font-size: 14px;\"><strong>Qu\u00e9 obtienes con MedsBase:<\/strong> Pharmaceutical-grade lyophilized peptides &middot; HPLC &ge;99% purity (COA on request) &middot; Discreet protective packaging &middot; Worldwide peptide courier &middot; 1,400+ verified <a href=\"https:\/\/medsbase.com\/es\/reviews\/\">opiniones de clientes<\/a><\/div>\n<p class=\"medsbase-reship-line\" style=\"font-size: 14px; color: #444; margin: 8px 0 18px;\">\ud83d\udce6 Cada pedido est\u00e1 cubierto por nuestra <a href=\"https:\/\/medsbase.com\/es\/medsbase-re-shipment-assurance-policy\/\"><strong>Reshipment Assurance Policy<\/strong><\/a> \u2014 si tu paquete no llega en 20 d\u00edas laborables, lo reenviamos.<\/p>\n<table class=\"medsbase-spec-table\" style=\"width: 100%; border-collapse: collapse; margin: 18px 0; font-size: 14px;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 8px 12px; text-align: left; width: 30%;\">Especificaci\u00f3n<\/th>\n<th style=\"padding: 8px 12px; text-align: left;\">Detalle<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>N\u00famero CAS<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">374675-21-5 (kisspeptina-10, humana)<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>F\u00f3rmula molecular<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">C<sub>63<\/sub>H<sub>83<\/sub>N<sub>17<\/sub>O<sub>14<\/sub><\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Peso molecular<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">1302.45 Da<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Secuencia<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Tyr-Asn-Trp-Asn-Ser-Phe-Gly-Leu-Arg-Phe-NH<sub>2<\/sub> (YNWNSFGLRF-NH<sub>2<\/sub>, 10 amino\u00e1cidos; fragmento activo amidado en el extremo C-terminal de la kisspeptina madura de 54 aa)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Forma<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Polvo liofilizado (blanco a blanquecino)<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Pureza<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">\u226599% (verificado por HPLC, COA bajo solicitud)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Almacenamiento<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Liofilizado: 2\u20138 \u00b0C (refrigerador) para stock de trabajo; \u221220 \u00b0C para almacenamiento a largo plazo de viales sin abrir. Reconstituido: 2\u20138 \u00b0C, usar dentro de ~30 d\u00edas. Proteger de la luz. No congelar-descongelar la soluci\u00f3n reconstituida.<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Solubilidad<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Agua bacteriost\u00e1tica (recomendada) o agua est\u00e9ril para periodos de uso m\u00e1s cortos<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><!-- \/medsbase-tldr-answer --><\/p>\n<h2>\u00bfQu\u00e9 es la Kisspeptina-10?<\/h2>\n<p><strong>Kisspeptina-10<\/strong> (KP-10) is a 10-amino-acid peptide and the most extensively studied active fragment of the KISS1 gene product, a 145-amino-acid preprokisspeptin that is processed into the 54-amino-acid mature kisspeptin and several shorter C-terminal active fragments (kisspeptin-14, kisspeptin-13, kisspeptin-10). All of the shorter fragments share the C-terminal 10-residue active core and have comparable potency at the kisspeptin receptor \u2014 kisspeptin-10 is the shortest fully active form and is by far the most common peptide in the kisspeptin literature. The well-characterised sequence is YNWNSFGLRF-NH<sub>2<\/sub>, peso molecular 1302.45\u00a0Da, f\u00f3rmula emp\u00edrica C<sub>63<\/sub>H<sub>83<\/sub>N<sub>17<\/sub>O<sub>14<\/sub>. La amidaci\u00f3n en el extremo C-terminal es esencial para la actividad completa del receptor. KISS1 fue identificado originalmente como un gen supresor de met\u00e1stasis por Lee et al. (Cancer Res 1996) y fue renombrado kisspeptina en honor a Hershey, Pensilvania (hogar de los chocolates Hershey\u2019s Kisses) donde el gen fue clonado por primera vez. El papel reproductivo \u2014 KISS1\/GPR54 como el regulador apical de las neuronas GnRH y el guardi\u00e1n molecular de la pubertad \u2014 fue establecido por dos art\u00edculos independientes en 2003 (Seminara et al., NEJM; de Roux et al., PNAS) que demostraron que las mutaciones de p\u00e9rdida de funci\u00f3n en GPR54 causan hipogonadismo hipogonadotr\u00f3pico idiop\u00e1tico en humanos. La kisspeptina-10 se suministra como un polvo liofilizado de alta pureza para reconstituci\u00f3n con agua bacteriost\u00e1tica. Est\u00e1 <strong>no est\u00e1 aprobado<\/strong> by the FDA, EMA, MHRA, or any other major regulator for human therapeutic use, although ongoing IVF and infertility is investigating clinical applications. <\/p>\n<h2>Mecanismo de Acci\u00f3n \u2014 Se\u00f1alizaci\u00f3n de GPR54 \/ KISS1R y el Eje HPG<\/h2>\n<p>What makes kisspeptin-10 mechanistically distinctive among reproductive-peptides is its position as the <strong>regulador apical ascendente<\/strong> of the entire hypothalamic-pituitary-gonadal (HPG) axis. The peptide acts at a single receptor \u2014 GPR54 (also called KISS1R) \u2014 but the downstream cascade controls the full reproductive endocrine system in published studies:<\/p>\n<ul>\n<li><strong>Activaci\u00f3n de GPR54 (KISS1R) en neuronas GnRH<\/strong> \u2014 La kisspeptina-10 se une a GPR54, un receptor acoplado a prote\u00edna G de clase A expresado densamente en los cuerpos celulares de las neuronas GnRH en los n\u00facleos arcuato y anteroventral periventricular del hipot\u00e1lamo. La activaci\u00f3n del receptor se acopla a G\u03b1<sub>q\/11<\/sub> y fosfolipasa C, aumentando el calcio intracelular y desencadenando la despolarizaci\u00f3n de las neuronas de GnRH y la liberaci\u00f3n puls\u00e1til de GnRH en el sistema portal hipofisario. Este es el mecanismo m\u00e1s directo: la activaci\u00f3n de las neuronas de GnRH es el paso limitante de la actividad del eje HPG, y la kisspeptina es el principal est\u00edmulo end\u00f3geno.<\/li>\n<li><strong>Regulaci\u00f3n del eje HPG en modo puls\u00e1til frente a modo de oleada<\/strong> \u2014 Kisspeptin neurons in the arcuate nucleus drive the pulsatile GnRH\/LH pattern that maintains gonadal function throughout adult reproductive life. A separate population of kisspeptin neurons in the anteroventral periventricular nucleus (in rodents) generates the preovulatory LH surge in females. Studies using selective stimulation or knockout of these populations has dissected the two modes of HPG-axis output in published studies.<\/li>\n<li><strong>Inicio de la pubertad y el \u201cinterruptor de kisspeptina\u201d<\/strong> \u2014 Loss-of-function GPR54 mutations cause complete failure of puberty onset in humans and animal models; gain-of-function mutations cause central precocious puberty. The &#8220;kisspeptin switch&#8221; hypothesis \u2014 that puberty is initiated when arcuate kisspeptin neurons reach a critical activity threshold \u2014 is the dominant model of pubertal onset in current reproductive neuroscience studies.<\/li>\n<\/ul>\n<p>Kisspeptin-10 has a relatively short plasma half-life (~5\u201310 minutes) due to rapid proteolytic cleavage, particularly at the central RF amide motif by matrix metalloproteinases. Subcutaneous, intravenous, and intracerebroventricular routes are all documented in published studies; the central route is reserved for mechanism-of-action studies in rodents where the BBB-crossing question is relevant. For systemic HPG-axis studies, peripheral administration produces measurable GnRH\/LH responses within minutes of bolus injection. <\/p>\n<h2>Published Evidence<\/h2>\n<p>Kisspeptin-10 is used in clinical contexts that investigate:<\/p>\n<ul>\n<li><strong>Endocrinolog\u00eda reproductiva y farmacolog\u00eda del eje HPG<\/strong> \u2014 din\u00e1mica puls\u00e1til de GnRH\/LH\/FSH, regulaci\u00f3n por retroalimentaci\u00f3n gonadal, retroalimentaci\u00f3n de esteroides sexuales sobre la actividad de las neuronas de kisspeptina (Seminara et al., NEJM 2003; de Roux et al., PNAS 2003)<\/li>\n<li><strong>Puberty studies<\/strong> \u2014 cronolog\u00eda del inicio puberal en modelos de roedores, patrones de activaci\u00f3n de las neuronas de kisspeptina durante la transici\u00f3n puberal, disecci\u00f3n mecan\u00edstica de la pubertad precoz central<\/li>\n<li><strong>Hypogonadotropic hypogonadism studies<\/strong> \u2014 preclinical models of GPR54 loss-of-function, kisspeptin-replacement protocols, mechanism-of-action studies for novel hypogonadism therapies<\/li>\n<li><strong>IVF and ovulation induction studies<\/strong> \u2014 alternatives to hCG trigger in IVF protocols, comparative LH-surge induction; clinical translation has reached Phase 2 in some studies programmes although kisspeptin-10 itself is not approved<\/li>\n<li><strong>Polycystic ovary syndrome (PCOS) studies<\/strong> \u2014 altered kisspeptin tone in PCOS preclinical models, LH-pulse frequency abnormalities, follicular maturation studies<\/li>\n<li><strong>Supresi\u00f3n de met\u00e1stasis y biolog\u00eda del c\u00e1ncer<\/strong> \u2014 KISS1 was originally identified as a metastasis-suppressor gene; published studies continues to investigate kisspeptin&#8217;s anti-metastatic activity in breast, melanoma, and pancreatic cancer models<\/li>\n<li><strong>Cardiovascular and metabolic support<\/strong> \u2014 expresi\u00f3n emergente de KISS1R en cardiomiocitos y c\u00e9lulas \u03b2 pancre\u00e1ticas; efectos sobre la homeostasis de la glucosa y la contractilidad card\u00edaca bajo investigaci\u00f3n<\/li>\n<li><strong>Comparative reproductive peptide studies<\/strong> \u2014 evaluaci\u00f3n comparativa frente a <a href=\"https:\/\/medsbase.com\/es\/pt-141\/\">PT-141 (Bremelanotide)<\/a> for melanocortin-axis sexual-behaviour studies and against <a href=\"https:\/\/medsbase.com\/es\/oxytocin-acetate\/\">Oxitocina Acetato<\/a> para puntos finales de afiliaci\u00f3n y vinculaci\u00f3n social.<\/li>\n<\/ul>\n<p>Para un contexto m\u00e1s amplio sobre d\u00f3nde encaja la kisspeptina-10 en el panorama de los p\u00e9ptidos reproductivos y activos en el SNC, consulte <a href=\"https:\/\/medsbase.com\/es\/pt-141\/\">PT-141<\/a> (melanocortin agonist for sexual behaviour studies), <a href=\"https:\/\/medsbase.com\/es\/oxytocin-acetate\/\">Oxitocina Acetato<\/a> (neuropeptido de comportamiento afiliativo), y <a href=\"https:\/\/medsbase.com\/es\/sermorelin\/\">Sermorelin<\/a> (GHRH-axis hypothalamic-pituitary studies). Browse the full <a href=\"https:\/\/medsbase.com\/es\/peptides\/\">cat\u00e1logo de p\u00e9ptidos<\/a> para compuestos relacionados. <\/p>\n<h2>Concentraciones y potencias disponibles<\/h2>\n<p>MedsBase stocks Kisspeptin-10 in two lyophilized vial sizes calibrated to typical protocol lengths. Each strength is available in 10-vial, 20-vial, or 30-vial pack formats with full reconstitution guidance:<\/p>\n<table style=\"width: 100%; border-collapse: collapse; margin: 16px 0;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Potencia del vial<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Caso de uso t\u00edpico<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Tama\u00f1os de paquete<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>5 mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Standard strength \u2014 pilot dosing, HPG-axis pulse protocols, single-cohort studies<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10, 20 o 30 viales<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>10 mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Protocolos de ciclo extendido, estudios multicohorte, menor coste por mg<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10, 20 o 30 viales<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>Both strengths are the same chemical form (lyophilized powder, 99%+ HPLC purity). Higher-mg vials require smaller reconstitution volumes per unit dose, which is useful when users want to minimise injection volume in rodent protocols. Because kisspeptin-10 dose ranges are in the low-microgram regime per administration, a single 5\u00a0mg vial supports many weeks of pulse-protocol use at typical doses. <\/p>\n<h2>Comparativa \u2014 Kisspeptin-10 vs PT-141<\/h2>\n<p>Tanto Kisspeptin-10 como <a href=\"https:\/\/medsbase.com\/es\/pt-141\/\">PT-141 (Bremelanotide)<\/a> are both small CNS-active peptides used in reproductive- and sexual-behaviour studies, but they act on fundamentally different pathways. Kisspeptin-10 acts on the endocrine HPG axis at the GnRH-neuron level; PT-141 acts on the melanocortin behavioural-sexual axis at the MC4R level. The two are mechanistically complementary rather than competing in study models. <\/p>\n<table style=\"width: 100%; border-collapse: collapse; margin: 16px 0;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Criterio<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Kisspeptina-10<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">PT-141 (Bremelanotide)<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Longitud<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10 amino\u00e1cidos (decap\u00e9ptido)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">7 amino\u00e1cidos (heptap\u00e9ptido c\u00edclico)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Receptor primario<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Receptores GPR54 \/ KISS1R<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Receptores de melanocortina MC3R \/ MC4R<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Efecto principal<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Liberaci\u00f3n de GnRH\/LH\/FSH (endocrino)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Comportamiento sexual mediado por el SNC (conductual)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Studies domain<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Eje HPG, pubertad, hipogonadismo, FIV<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Deseo sexual, excitaci\u00f3n, funci\u00f3n er\u00e9ctil<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Vida media plasm\u00e1tica<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">~5\u201310 min<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">~2 horas (SC)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Uso cl\u00ednico aprobado<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">None (Phase 2 in IVF studies)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">FDA-approved as Vyleesi for HSDD (different molecule from pharmaceutical-grade)<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Dosis t\u00edpica<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10\u2013200 mcg, bolo o pulso<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">0.25\u20132 mg, administraci\u00f3n \u00fanica<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>The two peptides address different layers of reproductive biology \u2014 kisspeptin-10 the endocrine HPG axis, PT-141 the CNS-mediated behavioural axis \u2014 so they are not direct alternatives. Studies interested in pulsatile GnRH\/LH dynamics, puberty timing, or hypogonadism uses kisspeptin-10. Studies interested in CNS-mediated sexual-arousal pathways uses PT-141. <\/p>\n<h2>Almacenamiento y reconstituci\u00f3n<\/h2>\n<p><strong>Antes de la reconstituci\u00f3n:<\/strong> Almacene los viales liofilizados refrigerados a 2\u20138 \u00b0C en su envase original para stock de trabajo a corto plazo. Para almacenamiento a largo plazo sin abrir, congele a \u221220 \u00b0C. La kisspeptina-10 liofilizada es estable bajo refrigeraci\u00f3n hasta 24 meses y a \u221220 \u00b0C hasta 36 meses. Evite los ciclos de congelaci\u00f3n-descongelaci\u00f3n del polvo liofilizado. <strong>Procedimiento de reconstituci\u00f3n:<\/strong> inject bacteriostatic water down the side wall of the peptide vial (not directly onto the lyophilized cake). For a 5\u00a0mg vial, 2.0\u00a0mL of bacteriostatic water yields a 2.5\u00a0mg\/mL working concentration \u2014 0.04\u00a0mL delivers a 100\u00a0mcg dose. For lower-dose work, further dilution into bacteriostatic water (with optional BSA carrier protein at 0.1%) can be used. Swirl gently \u2014 do <strong>ajuste<\/strong> shake \u2014 and allow 2\u20135 minutes for full dissolution. A correctly reconstituted solution should be clear and colourless. <strong>Despu\u00e9s de la reconstituci\u00f3n:<\/strong> Almacene refrigerado a 2\u20138 \u00b0C y util\u00edcelo dentro de los 30 d\u00edas para una estabilidad \u00f3ptima. No congele la soluci\u00f3n reconstituida: los ciclos de congelaci\u00f3n-descongelaci\u00f3n degradan la integridad del p\u00e9ptido. Deseche cualquier vial que presente turbidez, precipitado o decoloraci\u00f3n. La kisspeptina-10 es susceptible a la escisi\u00f3n proteol\u00edtica en el motivo RF-amida del extremo C-terminal; la soluci\u00f3n reconstituida debe utilizarse r\u00e1pidamente dentro del plazo de 30 d\u00edas para protocolos que requieran una calibraci\u00f3n precisa de la relaci\u00f3n dosis-respuesta. <\/p>\n<h2 id=\"faqs\">Preguntas frecuentes<\/h2>\n<h3>What is Kisspeptin-10 used for in studies?<\/h3>\n<p>Kisspeptin-10 is used in studies investigating the hypothalamic-pituitary-gonadal (HPG) axis, GnRH neuron activity, pulsatile gonadotropin release, puberty onset, hypogonadotropic hypogonadism, polycystic ovary syndrome (PCOS), IVF and ovulation-induction alternatives to hCG, cancer metastasis suppression (KISS1 was originally identified as a metastasis-suppressor gene), and emerging cardiometabolic kisspeptin signalling. It is the canonical tool for KISS1R \/ GPR54 pharmacology. The pharmaceutical-grade kisspeptin-10 sold here is <strong>ajuste<\/strong> FDA-approved and is supplied strictly for clinical studies use only. <\/p>\n<h3>\u00bfEn qu\u00e9 se diferencia la kisspeptina-10 de la PT-141?<\/h3>\n<p>Both are small CNS-active reproductive peptides, but they target different receptors and biological layers. Kisspeptin-10 acts on the GPR54\/KISS1R receptor on GnRH neurons and drives the endocrine HPG axis (LH, FSH, gonadal steroid production). PT-141 acts on MC3R\/MC4R melanocortin receptors in the CNS and drives behavioural-sexual responses (desire, arousal, erectile function). The two are mechanistically complementary and address different studies questions. <\/p>\n<h3>\u00bfCu\u00e1l es la diferencia entre la kisspeptina-10 y la kisspeptina-54?<\/h3>\n<p>Both are active fragments of the KISS1 gene product. Kisspeptin-54 (also called metastin) is the full-length mature 54-amino-acid peptide secreted in vivo. Kisspeptin-10 is the C-terminal 10-amino-acid active core, which retains essentially full receptor potency and is the most commonly used peptide because its smaller size makes synthesis cheaper, purity easier to verify, and reconstitution simpler. Kisspeptin-13 and kisspeptin-14 are intermediate cleavage products that also share the active C-terminal core. All four have comparable potency at GPR54. <\/p>\n<h3>What is the typical Kisspeptin-10 dose?<\/h3>\n<p>Published preclinical protocols typically use 10\u2013200\u00a0mcg per administration in rodent models, given subcutaneously or intravenously for bolus-pulse studies, or as continuous infusion for chronic-stimulation studies. Human IVF has used 6.4\u201312.8\u00a0\u03bcg\/kg as a single subcutaneous trigger dose. A 5\u00a0mg vial reconstituted with 2.0\u00a0mL bacteriostatic water yields 2.5\u00a0mg\/mL \u2014 0.04\u00a0mL equals 100\u00a0mcg. <\/p>\n<h3>\u00bfEst\u00e1 la kisspeptina-10 aprobada por la FDA?<\/h3>\n<p>No. Kisspeptin-10 is not approved by the FDA, EMA, MHRA, or any other major regulator for human therapeutic use. Phase 2 clinical studies in IVF ovulation induction is ongoing, but kisspeptin-10 has not been approved for any clinical indication. <\/p>\n<h3>\u00bfC\u00f3mo debe almacenarse la kisspeptina-10?<\/h3>\n<p>Viales liofilizados: refrigerar a 2\u20138 \u00b0C para stock de trabajo a corto plazo, o a \u221220 \u00b0C para almacenamiento a largo plazo de viales sin abrir. Soluci\u00f3n reconstituida: refrigerar a 2\u20138 \u00b0C, usar en un plazo de 30 d\u00edas. No congelar la soluci\u00f3n reconstituida \u2014 los ciclos de congelaci\u00f3n-descongelaci\u00f3n degradan el p\u00e9ptido. Proteger siempre de la luz directa. Para diluciones de trabajo de baja concentraci\u00f3n, se recomienda prote\u00edna transportadora BSA (0,1%) para minimizar las p\u00e9rdidas por adsorci\u00f3n. <\/p>\n<h3>\u00bfC\u00f3mo reconstituyo Kisspeptin-10?<\/h3>\n<p>Siga el procedimiento de reconstituci\u00f3n anterior. A\u00f1ada agua bacteriost\u00e1tica por la pared lateral del vial (no sobre el polvo liofilizado), agite suavemente y permita de 2 a 5 minutos para la disoluci\u00f3n completa. No <strong>ajuste<\/strong> agite el vial. Una soluci\u00f3n correctamente reconstituida es transparente e incolora. Para un vial de 5 mg + 2,0 mL de diluyente, la concentraci\u00f3n de trabajo es de 2,5 mg\/mL. <\/p>\n<h3>\u00bfQu\u00e9 concentraciones tiene MedsBase en stock?<\/h3>\n<p>MedsBase carries Kisspeptin-10 in 5\u00a0mg and 10\u00a0mg lyophilized vials. Each strength is available in 10-vial, 20-vial, or 30-vial pack sizes. All vials are supplied at 99%+ HPLC purity with a certificate of analysis available on request. <\/p>\n<h3>\u00bfPor qu\u00e9 se llam\u00f3 originalmente kisspeptina al gen KISS1?<\/h3>\n<p>El gen KISS1 fue descubierto como un gen supresor de met\u00e1stasis por Lee et al. en Hershey, Pensilvania (Cancer Res 1996). El nombre \u201ckisspeptina\u201d era una referencia ir\u00f3nica a los Hershey\u2019s Kisses, los ic\u00f3nicos chocolates producidos en la misma ciudad. El papel reproductivo no se caracteriz\u00f3 hasta 2003 con la publicaci\u00f3n simult\u00e1nea de estudios sobre hipogonadismo por mutaci\u00f3n en GPR54 humano en NEJM (Seminara et al.) y PNAS (de Roux et al.). As\u00ed, el p\u00e9ptido tiene la inusual distinci\u00f3n de ser caracterizado independientemente tanto como supresor de met\u00e1stasis cancer\u00edgenas como regulador apical de la pubertad \u2014 dos roles que a\u00fan no est\u00e1n completamente conectados a nivel mecan\u00edstico. <\/p>\n<h3>Does Kisspeptin-10 cause side reported effects?<\/h3>\n<p>Published preclinical and Phase 1\/2 clinical studies has documented good tolerability at typical doses. The predominant on-target effects are HPG-axis activation \u2014 rising LH, FSH, testosterone (males) or estradiol (females), and downstream gonadal steroid effects. Off-target findings include modest cardiovascular effects mediated by KISS1R expression on vascular tissue, and a flushing\/vasodilation effect noted in some human studies at higher doses. Long-term safety data outside contexts is limited. <\/p>\n<h3>\u00bfCu\u00e1l es la vida media del Kisspeptin-10?<\/h3>\n<p>In preclinical and clinical studies, kisspeptin-10 has a plasma half-life of approximately 5\u201310 minutes following intravenous or subcutaneous administration. The short half-life is due to rapid proteolytic cleavage by matrix metalloproteinases at the central RF-amide motif. For chronic-stimulation studies, continuous infusion or repeated pulse-dosing protocols are used to maintain receptor occupancy. <\/p>\n<h3>How long does Kisspeptin-10 take to show effects in preclinical studies?<\/h3>\n<p>Acute LH responses to bolus kisspeptin-10 administration are detectable within 5\u201315 minutes in rodent and human studies. FSH and downstream gonadal steroid responses develop over hours to days. Chronic-stimulation effects on puberty timing in young rodent models manifest over the natural pubertal window \u2014 days to weeks depending on species and developmental stage at intervention. <\/p>\n<h3>\u00bfPuedo pedir Kisspeptin-10 para env\u00edo internacional?<\/h3>\n<p>S\u00ed. MedsBase env\u00eda Kisspeptin-10 a todo el mundo desde nuestra red de env\u00edo dedicada a p\u00e9ptidos. Los pedidos que solo contienen p\u00e9ptidos califican para nuestro servicio de env\u00edo independiente de p\u00e9ptidos. Todos los pedidos se env\u00edan en embalaje con control de temperatura con seguimiento completo y est\u00e1n cubiertos por nuestro <a href=\"https:\/\/medsbase.com\/es\/medsbase-re-shipment-assurance-policy\/\">Reshipment Assurance Policy<\/a>. <!-- medsbase-related-alts-v1 --><\/p>\n<h2>Other Peptides for Reproductive, CNS, and Behavioural Studies<\/h2>\n<ul>\n<li><a href=\"\/es\/pt-141\/\"><strong>PT-141 (Bremelanotide)<\/strong><\/a> \u2014 Cyclic heptapeptide melanocortin agonist \u2014 CNS-mediated sexual-behaviour studies<\/li>\n<li><a href=\"\/es\/oxytocin-acetate\/\"><strong>Oxitocina Acetato<\/strong><\/a> \u2014 9-aa cyclic neuropeptide \u2014 social-bonding and affiliative behavioural support<\/li>\n<li><a href=\"\/es\/sermorelin\/\"><strong>Sermorelin<\/strong><\/a> \u2014 GHRH(1-29) analog \u2014 hypothalamic-pituitary-axis studies<\/li>\n<li><a href=\"\/es\/cjc-1295-with-dac\/\"><strong>CJC-1295 con DAC<\/strong><\/a> \u2014 Long-acting GHRH analog \u2014 growth-axis studies<\/li>\n<li><a href=\"\/es\/selank\/\"><strong>Selank<\/strong><\/a> \u2014 Anxiolytic heptapeptide \u2014 GABA \/ BDNF stress resilience<\/li>\n<\/ul>\n<p><!-- medsbase-peptide-guide-cta --><\/p>\n<h2>Lecturas adicionales<\/h2>\n<div style=\"background: #f4f8fb; border-left: 4px solid #2c7cb0; padding: 18px 22px; margin: 18px 0; border-radius: 4px;\">\n<p style=\"margin: 0 0 8px 0;\"><strong>\ud83d\udcd6 Explore reproductive and CNS-active peptides<\/strong><\/p>\n<p style=\"margin: 0;\">Explora toda la <a href=\"https:\/\/medsbase.com\/es\/peptides\/\"><strong>cat\u00e1logo de p\u00e9ptidos<\/strong><\/a>, con compuestos relacionados que incluyen <a href=\"https:\/\/medsbase.com\/es\/pt-141\/\">PT-141 (Bremelanotide)<\/a> for melanocortin sexual-behaviour studies, <a href=\"https:\/\/medsbase.com\/es\/oxytocin-acetate\/\">Oxitocina Acetato<\/a> for affiliative-behaviour studies, and <a href=\"https:\/\/medsbase.com\/es\/sermorelin\/\">Sermorelin<\/a> for hypothalamic-pituitary-axis studies.<\/p>\n<\/div>\n<p><!-- pep-seo-v1 --><\/p>","protected":false},"excerpt":{"rendered":"<p>\u2705 Regulador apical de la actividad neuronal de GnRH<br \/>\n\u2705 Agonista del receptor KISS1R \/ GPR54<br \/>\n\u2705 HPG-axis &amp; puberty compound<br \/>\n\u2705 IVF and ovulation-induction studies<br \/>\n\u2705 Identificado originalmente como supresor de met\u00e1stasis<\/p>\n<p><strong>Kisspeptina-10<\/strong> contiene compuesto de p\u00e9ptido sint\u00e9tico.<\/p>","protected":false},"featured_media":70963,"comment_status":"open","ping_status":"closed","template":"","meta":[],"product_brand":[],"product_cat":[5426],"product_tag":[6277,5441],"class_list":["post-70723","product","type-product","status-publish","has-post-thumbnail","product_cat-peptides","product_tag-kisspeptin","product_tag-peptide","first","instock","shipping-taxable","purchasable","product-type-variable","has-default-attributes"],"acf":[],"_links":{"self":[{"href":"https:\/\/medsbase.com\/es\/wp-json\/wp\/v2\/product\/70723","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medsbase.com\/es\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/medsbase.com\/es\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/medsbase.com\/es\/wp-json\/wp\/v2\/comments?post=70723"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medsbase.com\/es\/wp-json\/wp\/v2\/media\/70963"}],"wp:attachment":[{"href":"https:\/\/medsbase.com\/es\/wp-json\/wp\/v2\/media?parent=70723"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/medsbase.com\/es\/wp-json\/wp\/v2\/product_brand?post=70723"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/medsbase.com\/es\/wp-json\/wp\/v2\/product_cat?post=70723"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/medsbase.com\/es\/wp-json\/wp\/v2\/product_tag?post=70723"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}